Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content. Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

Navigating Billing for Pharmacy Services

(ACCCBuzz Blog) Nov 19, 2020 - Integrating pharmacists into oncology care delivery models has shown to improve outcomes1 for patients and boost the financial stability of cancer programs and practices. But billing for pharmacy services can be onerous and complicated.

Breast Cancer Discovery Could Help Stop Disease’s Deadly Spread

(University of Virginia) Nov 20, 2020 - A UVA research team found that the breast cancer oncogene TRIM37 not only causes the cancer to spread but also makes it resistant to chemotherapy.

National Comprehensive Cancer Network® Adds INQOVI® (decitabine and cedazuridine) Tablets to its Clinical Practice Guidelines in Oncology for Myelodysplastic Syndromes

(Yahoo!) Nov 23, 2020 – Taiho Oncology, Inc. today announced that the FDA approved hypomethylating agent INQOVI® (decitabine and cedazuridine) 35 mg/100 mg tablets, for oral use, has been included in the latest National Comprehensive Cancer Network® Clinical Practice Guidelines (NCCN Guidelines®) in Oncology for Myelodysplastic Syndromes (MDS).

Draft FDA Guidance Addresses Oncology Drug Cross Labeling

(Regulatory Focus) Nov 20, 2020 - In response to increasing requests from sponsors applying for oncology drugs intended to be used in combination regimens, the US Food and Drug Administration has released draft guidance for how oncology drugs used in combination regimens can be referenced by means of cross-labeling. "Oncology drug applications to the FDA often add investigational drugs to current regimens to create new combination regimens with greater efficacy or safety,” said Richard Pazdur, MD, director of FDA’s Center of Oncology Excellence and acting director of the Office of Oncologic Diseases in the Center for Drug Evaluation and Research.

Israeli Scientists: New Cancer Treatment Like Using ‘Tiny Scissors’ To Hit Cells

(New York Post) Nov 22, 2020 - Israeli scientists say they’ve created a way to treat cancer in mice that is so precise, it’s like using “tiny scissors” to target the cells, according to a report.

Inaugural Class Of FDA-AACR Oncology Educational Fellows Announced

(Healio) Nov 22, 2020 - American Association for Cancer Research announced the 2020-2021 class of FDA-AACR oncology educational fellows.

OneOncology & Genentech Bring Personalized Cancer Research to Patients at Community Oncology Sites

(OneOncology) Nov 23, 2020 - Collaboration will advance comprehensive genomic profiling, clinical trials and real-world data studies for cancer patients. MyTACTIC precision basket trial is scheduled to launch in December 2020 at community oncology centers including OneOncology. OneOncology, the national partnership of independent oncology practices, and Genentech, a member of the Roche Group, today announced the first clinical trial available to patients through OneR, the OneOncology Research Network.

Adaptive Biotechnologies and Collaborators to Present Data from More Than 35 Abstracts at ASH 2020 Highlighting Clinical Relevance of MRD Testing with the clonoSEQ® Assay in Blood Cancer Patients

(Yahoo! News) Nov 23, 2020 - Adaptive Biotechnologies Corporation, a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, together with its collaborators will present data from more than 35 abstracts studying the use of Adaptive’s clonoSEQ® Assay for minimal residual disease (MRD) assessment at the American Society of Hematology (ASH) virtual 62nd Annual Meeting and Exposition, December 5-8.

First Opinion: The National Cancer Institute Needs To Publish Information About Chemical Exposure And Cancer Risk

(STAT) Nov 21, 2020 - Our government should take the steps it can to protect Americans from a public health crisis that is claiming thousands of lives. We aren’t just talking about Covid-19 here. We are talking about breast cancer.

Immunocore’s Tebentafusp Demonstrates Superior Overall Survival Compared to Investigator’s Choice in a Phase 3 Clinical Trial Of Patients With Previously Untreated Metastatic Uveal Melanoma

(Immunocore) Nov 23, 2020 - First positive Phase 3 clinical trial for any T cell receptor therapeutic and first for any bispecific in a solid tumor. Tebentafusp has the potential to be the first new therapy to improve OS in patients with metastatic uveal melanoma in 40 years. Immunocore today announced that its Phase 3 IMCgp100-202 clinical trial of tebentafusp (IMCgp100) vs. investigator choice in metastatic uveal melanoma (mUM) has met the pre-defined boundaries for statistical significance of the primary endpoint of Overall Survival (OS) in its first pre-planned interim analysis conducted by the independent data monitoring committee.